Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets

Biomolecules and Therapeutics

Volumn 21, Issue 1, 2013, Pages 54-59

  Lee, Dong Ha ^a   Kim, Yun Jung ^a   Kim, Hyun Hong ^a   Cho, Hyun Jeong ^b   Ryu, Jin Hyeob ^a   Rhee, Man Hee ^c   Park, Hwa Jin ^a  

^a Inje University   (South Korea)

^b Konyang University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

( ) Epigallocatechin 3 gallate (EGCG); Aspirin; Cyclooxygenase 1; Microsomal fraction; Thromboxane synthase

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; EPIGALLOCATECHIN GALLATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; THROMBOXANE A2; THROMBOXANE SYNTHASE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; MALE; MICROSOME; NONHUMAN; PLATELET MICROSOMAL FRACTION; PROTEIN EXPRESSION; RAT; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

EID: 84873393617     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2012.075     Document Type: Article

References (36)

1. Armstrong, R. A. (1996) Platelet prostanoid receptors. Pharmacol. Ther. 72, 171-191.
2. Berenbaum, M. C. (1989) What is synergy? Pharmacol. Rev. 41, 93- 141.
3. Carey, F., Menashi, S. and Crawford, N. (1982) Localization of cyclooxygenase and thromboxane synthase in human platelet intracellular membranes. Biochem. J. 204, 847-851.
4. Cho, H. J., Kang, H. J., Kim, Y. J., Lee, D. H., Kwon, H. W., Kim, Y. Y. and Park, H. J. (2012) Inhibition of platelet aggregation by chlorogenic acid via cAMP and cGMP-dependent manner. Blood Coagul. Fibrinolysis 23, 629-635.
5. Clutton, P, Folts, J. D. and Freedman, J. E. (2001) Pharmacological control of platelet function. Pharmacol. Res. 44, 255-264.
6. Deana, R., Turetta, L., Donella-Deana, A., Dona, M., Brunati, A. M., Demichiel, L. and Garbisa, S. (2003) Green tea epigallocatechin-3-gallate inhibits platelet signaling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb. Haemost. 89, 866-874.
7. DeWitt, D. L., el-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. F., Amstrong, R. L. and Smith, W. L. (1990) The aspirin and hemebinding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265, 5192-5198.
8. 2 as an amplifying signal for other agonists. Am. J. Cardiol. 68, 11B-15B.
9. Gaddum, J. H. (1940) Pharmacology, Oxford University Press, London, 378-383.
10. Gresele, P., Deckymyn, H., Nenci, G. G. and Vermylen, J. (1991) Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. 12, 158-163.
11. Hamberg, M., Svensson, J. and Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72, 2994-2998.
12. Hussain, T., Gupta, S., Adhami, V. M. and Mukhtar, H. (2005) Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinnoma cells. Int. J. Cancer 113, 660-669.
13. Jang, E. K., Azzam, J. E., Dickinson, N. T., Davidson, M. M. and Haslam, R. J. (2002) Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside. Br. J. Haematol. 117, 664-675.
14. Jeng, J. H., Wu, H. L., Lin, B. R., Lan, W. H., Chang, H. H., Ho, Y. S., Lee, P. H., Wang, Y. J., Wang, J. S., Chen, Y. J. and Chang, M. C. (2007) Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production. Atherosclerosis 191, 250-258.
15. Jennings, L. K. (2009) Role of platelets in atherothrombosis. Am. J. Cardiol. 103, 4A-10A.
16. 2 production, and maintaining calcium- ATPase activity. J. Cardiovasc. Pharmacol. 51, 45-54.
17. 2 and diglyceride lipase activities in human platelet intracellular membranes. FEBS. Lett. 124, 23-26.
18. 2 production associated microsomal enzyme activity in platelets. J. Ginseng. Res. 36, 40-46.
19. 2 and adenosine diphosphate in collagen-induced aggregation of rabbit platelets. Br. J. Pharmacol. 75, 623-631.
20. Li, Z., Delaney, M. K., O'Brien, K. A. and Du, X. (2010) Signaling during platelet adhesion and activation. Arteroscler. Thromb. Vasc. Biol. 30, 2341-2349.
21. Lill, G., Voit, S., Schor, K. and Weber, A. A. (2003) Complex effects of different green tea catechins on human platelets. FEBS. Lett. 546, 265-270.
22. Malmsten, C., Hamberg, M., Svensson, J. and Samuelsson, B. (1975) Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclooxygenase deficiency. Proc. Natl. Acad. Sci. USA 72, 1446-1450.
23. Mancuso, M., Filosto, M., Bosetti, F., Ceravolo R., Rocchi, A., Tognoni, G, Manca, M. L., Solaini, G., Siciliano, G. and Murri, L. (2003) Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp. Neurol. 182, 421-426.
24. Ok, W. J., Cho, H. J., Kim, H. H., Lee, D. H., Kang, H. Y., Kwon, H. W., Rhee, M. H., Kim, M. and Park H. J. (2012) Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. J. Atheroscler. Thromb. 19, 337-348.
25. Park, J. B. (2007) Caffedymine from cocoa has COX inhibitory activity suppressing the expression of a platelet activation marker, p-selectin. J. Agric. Food Chem. 55, 2171-2175.
26. Patrono, C. (2001) Aspirin: New cardiovascular uses for an old drug. Am. J. Med. 110, 62S-65S.
27. Peng, G., Dixon, D. A., Muga, S. J., Smith, T. J. and Wargovich, M. J. (2006) Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol. Carcinog. 45, 309-319.
28. Pignone, M. and Williams, C. D. (2010) Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat. Rev. Endocrinol. 6, 619-628.
29. Roth, G. J., Stanford, N. and Majerus, P. W. (1975) Acetylation of prostaglandin synthase by aspirin. Proc. Nat. Acad. Sci. USA 72, 3073-3076.
30. Ruggeri, Z. M. (2002) Platelets in atherothrombosis. Nat. Med. 8, 1227-1234.
31. Samokovlisky, A., Rimon, G. and Danon, A. (1999) Differential regulation of cyclooxygenase isoenzymes by cAMP-elevating agents. Eur. J. Pharmacol. 378, 203-211.
32. Samuelsson, B., Goldyne, M., Granstrom, E., Mamberg, M., Hammarstrom, S. and Malmsten, C. (1978) Prostaglandin and thromboxanes. Annu. Rev. Biochem. 47, 997-1029.
33. Sanmuganathan, P. S., Ghahramani, P., Jackson, P. R., Wallis, E. J. and Ramsay, L. E. (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 85, 265-271.
34. Schafer, A. I., Levine, S. and Handin, R. I. (1980) Regulation of platelet arachidonic acid oxygenation by cyclic AMP. Blood 56, 853-858.
35. Schwartz, S. M., Heinmark, R. L. and Majesky, M. W. (1990) Developmental mechanisms underlying pathology of arteries. Physiol. Rev. 70, 1177-1209.
36. Trebino, C. E., Stock, J. L., Gibbons, C. P., Naiman, B. M., Wachtmann, T. S., Umland, J. P., Pandher, K., Lapointe, J. M., Saha, S., Roach, M. L., Carter, D., Thomas, N. A., Durtschi, B. A., McNeish, J. D., Hambor, J. E., Jakobsson, P. J., Carty, T. J., Perez, J. R. and Audoly, L. P. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Nat. Acad. Sci. USA 100, 9044-9049.